diphenhydramine and Abdominal Migraine

diphenhydramine has been researched along with Abdominal Migraine in 26 studies

Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.
diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.
antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.

Research

Studies (26)

Authors

Clinical Trials (9)

Trial Overview

Trial Outcomes

Number of Participants Needing Rescue Medication as Assessed by Questionnaire

Data collected by telephone. Patients were asked if they needed additional medication after discharge in order to reduce level of pain. This additional medication is considered rescue medication. (NCT02389829)
Timeframe: 48 hours after discharge from Emergency Department

Number of Participants Who Achieved Short Term Headache Freedom; Assessed by Telephone Questionnaire

Participants were asked to evaluate pain status since discharge. Participants who achieved total headache freedom for at least 1 hour are considered to achieve short term headache relief. (NCT02389829)
Timeframe: 48 hours after discharge from Emergency Department

Number of Participants Who Achieved Short Term Headache Relief, Assessed by Telphone Questionnaire

"Participants were asked to make evaluation of pain status since discharge. Those achieving headache level mild or none for 1 hour are considered to achieve short term headache relief." (NCT02389829)
Timeframe: 48 hours after discharge from Emergency Department

Number of Participants With Sustained Headache Relief Assessed by Self-evaluation

"Sustained headache relief is defined as achieving a headache level of mild or none within two hours and maintaining a level of mild or none for 48 hours, without use of addition medication. Patient self-evaluated pain level is solicited every half hour for two hours in the Emergency Department and then by telephone 48 hours after medication administration." (NCT02389829)
Timeframe: up to 2 hours in Emergency Department, 48 hours after discharge from Emergency Department

Length of Stay

Length of emergency department stay (NCT02933060)
Timeframe: 1 day

Percentage of Patients Free of Pain at 2 Hours

Percentage of patients in each group who are pain-free two hours after initiation of the study intervention. (NCT02933060)
Timeframe: 120 minutes

Percentage of Patients Reporting no Nausea or Mild Nausea at 60 Minutes

Patients reporting no nausea or mild nausea (NCT02933060)
Timeframe: 60 mins

Percentage of Patients Who Needed Rescue Medications

Need for additional medications for pain control as determined by the treating physician. (NCT02933060)
Timeframe: 120 minutes

Percentage of Patients Who Would Want the Same IV Fluid Treatment on a Future Visit

"Percentage of participants answering yes to the question: The next time you visit the ED with a headache, would you wish to receive the same IV fluid treatment again?" (NCT02933060)
Timeframe: 48 hours

Percentage of Patients With no or Mild Functional Disability Due to Headache at 60 Minutes

Percentage of patients with functional disability due to headache rated as none or mild (able to perform all activities of daily living, but with some difficulty) at 60 minutes (NCT02933060)
Timeframe: 60 minutes

Verbal Pain Score at 120 Minutes

The difference in verbal pain rating (0 = no pain, 10 = maximum pain) between the start of the study intervention and 2 hours later. The minimum clinically significant difference between treatment groups on the 0-10 verbal scale is 1.3. (NCT02933060)
Timeframe: 120 minutes

Verbal Pain Score at 48 Hours

Current pain as reported by participants at 48 hour follow-up (0-10 verbal scale; 0 = No Pain, 10 = Maximum Pain). (NCT02933060)
Timeframe: 48 hours

Verbal Pain Score at 60 Minutes

The primary outcome will be the difference in verbal pain rating (0 = no pain, 10 = maximum pain) between the start of the study intervention and one hour later, at completion of the intervention. The minimum clinically significant difference between treatment groups on the 0-10 verbal scale is 1.3. (NCT02933060)
Timeframe: 60 minutes

Verbal Report of Insertion Site Pain Score at 60 Minutes

Pain at IV insertion site (0 = No Pain, 10 = Maximum Pain) (NCT02933060)
Timeframe: 60 minutes

Number of Participants With Sustained Headache Relief Assessed by Self-evaluation

"Sustained headache relief is defined as achieving a headache level of mild or none within two hours and maintaining a level of mild or none for 48 hours. Patient self-evaluated pain level is solicited every half hour for two hours in the Emergency Department and then by telephone 48 hours after discharge from emergency department" (NCT01825941)
Timeframe: up to 2 hours in Emergency Department, 48 hours after discharge from Emergency Department

Anxiety

Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum anxiety. A change of 0 mm corresponds to no change in anxiety level, and a negative value indicates worsening of the anxiety after the medication. (NCT02657031)
Timeframe: 0-60 minutes

Headache Following Intervention

Reduction in 100 mm Visual Analog Scale (VAS) Score. Positive values represent a reduction in headache severity. The maximum possible change in VAS score is 100 mm, representing the complete relief of a maximally severe headache. A change of 0 mm corresponds to no change in headache severity, and a negative value indicates worsening of the headache after the medication. (NCT02657031)
Timeframe: 0-60 minutes

Nausea

Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum nausea. A change of 0 mm corresponds to no change in nausea level, and a negative value indicates worsening of the nausea after the medication. (NCT02657031)
Timeframe: 0-60 minutes

The Number of Participants Experiencing Vomiting

Yes/No (NCT02657031)
Timeframe: 0-60 minutes

The Number of Patients Experiencing Restlessness

Yes/No (NCT02657031)
Timeframe: 0-60 minutes

Reviews

1 review available for diphenhydramine and Abdominal Migraine

Trials

11 trials available for diphenhydramine and Abdominal Migraine

Other Studies

14 other studies available for diphenhydramine and Abdominal Migraine